Status:
COMPLETED
Polygen Defi-Alpha: Genetic Polymorphisms Study in Children With Alpha-1 Antitrypsin Deficiency, Included in the DEFI-ALPHA Cohort
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Children With a Deficiency of Alpha-1 Antitrypsin
Eligibility:
All Genders
7+ years
Phase:
NA
Brief Summary
The deficiency of alpha-1 antitrypsin (DA1AT) is a genetic disorder of variable clinical expression, initially described in adults with pulmonary emphysema patients. In children, it is the second caus...
Eligibility Criteria
Inclusion
- Children included in the DefiAlpha cohort or adult aged under 18 years at the time of inclusion in the cohort Defi-Alpha, with a deficiency of of alpha-1 antitrypsin
- Beneficiaries subjects of a social security system
- Presence of a signed informed consent (patient or parents) at the time of inclusion
Exclusion
- \- Lack of consent
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2017
Estimated Enrollment :
296 Patients enrolled
Trial Details
Trial ID
NCT01862211
Start Date
May 1 2013
End Date
November 1 2017
Last Update
December 19 2025
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU d'Amiens - Hopital Nord
Amiens, France
2
CHU de BESANCON
Besançon, France
3
Hôpital Pellegrin
Bordeaux, France
4
Hôpital Femme Mère Enfant de Lyon
Bron, France